Information Provided By:
Fly News Breaks for November 13, 2018
AMRN, MTNB
Nov 13, 2018 | 07:47 EDT
Maxim analyst Jason McCarthy raised his price target on Matinas BioPharma (MTNB) to $5 and kept his Buy rating after its Q3 results. The analyst adds that he is also factoring in the impact of MAT9001 after the outcome of data evaluating Amarin's (AMRN) Vascepa + Statin, and the company's decision to move MAT9001 forward for hypertriglyceridemia.
News For MTNB;AMRN From the Last 2 Days
There are no results for your query MTNB;AMRN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.